Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03492671 · ClinicalTrials.gov registry record · Phase 2
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
A Phase 2 study of Pancreas Adenocarcinoma and Resectable Pancreatic Cancer, sponsored by Loma Linda University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03492671: Recruiting Phase 2 study of Pancreas Adenocarcinoma and Resectable Pancreatic Cancer, sponsored by Loma Linda University.
NCT03492671 is a Phase 2 study of Pancreas Adenocarcinoma and Resectable Pancreatic Cancer that is actively recruiting participants, run by Loma Linda University. The registered enrollment target is 30 participants, below the 76-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03492671, a Phase 2 study of Pancreas Adenocarcinoma and Resectable Pancreatic Cancer, is actively recruiting participants, sponsored by Loma Linda University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectable pancreactic cancer, can help to increase the chances of surgeons achieving and R0 resection. The chemotherapy drugs used are gemcitabine and nab-paclitaxel. These drugs are both approved by the FDA for use in treating adults with pancreatic adenocarcinoma. The investigational portion of this study is providing the chemotherapy drugs and radiation therapy before surgery. Primary Endpoint, R) resection rate ≥70%. Secondary Endpoints, Disease free survival, Overall survival , Perioperative mortality and morbidity.
Primary Outcome
Measure the rate of R0 resection with all margins microscopically clear.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- DRUG nab-paclitaxel
- DRUG Gemcitabine 1000 mg
Study Locations (1)
California
- Loma Linda University Health - Loma Linda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-07-17 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT03492671 shows while recruiting
NCT03492671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 76-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (61% lower).
The record links to 2 conditions, with Pancreas Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT03492671 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03492671 about?
NCT03492671 is a clinical study titled "Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer". The purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectable pancreactic cancer, can help to increase the chances of surgeons achieving and R0 resection. The chemotherapy drugs used are gemcitabine a...
What is the current status of trial NCT03492671?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-07-17. Estimated completion is 2026-09.
What conditions does trial NCT03492671 study?
This clinical trial studies the following conditions: Pancreas Adenocarcinoma, Resectable Pancreatic Cancer.
What interventions are being tested in trial NCT03492671?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), nab-paclitaxel (DRUG), Gemcitabine 1000 mg (DRUG).
Who is sponsoring clinical trial NCT03492671?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03492671 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03492671's enrollment target sits among peer trials
30 9th of 10 higher than 2 of 10 other Pancreas Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
RECRUITING · Phase 2
-
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
RECRUITING · Phase 2
-
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
ACTIVE NOT RECRUITING · Phase 2
-
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI